A5038404398- Cancer Research and Treatments
- RNA modifications and cancer
- RNA Research and Splicing
- Toxin Mechanisms and Immunotoxins
- Gene expression and cancer classification
- Cancer, Hypoxia, and Metabolism
- Neuroblastoma Research and Treatments
- Epigenetics and DNA Methylation
- Bacteriophages and microbial interactions
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Cancer, Stress, Anesthesia, and Immune Response
- Molecular Biology Techniques and Applications
- Cytokine Signaling Pathways and Interactions
- Microtubule and mitosis dynamics
- MicroRNA in disease regulation
- bioluminescence and chemiluminescence research
- Cancer-related molecular mechanisms research
- Photodynamic Therapy Research Studies
- Prostate Cancer Treatment and Research
- Neuroendocrine Tumor Research Advances
- Nanoplatforms for cancer theranostics
- Receptor Mechanisms and Signaling
- Lung Cancer Research Studies
- Radiopharmaceutical Chemistry and Applications
National Cancer Institute
2019-2025
National Institutes of Health
2021-2025
University of Oxford
2020-2022
Center for Cancer Research
2019-2021
Office of the Director
2020
LMB-100 is a recombinant immunotoxin (iTox) consisting of mesothelin-binding Fab for targeting and modified Pseudomonas exotoxin A payload. Preclinical studies showed that combining taxanes with iTox results in synergistic antitumor activity. The objectives this phase I/II study were to determine the MTD when administered nanoalbumin bound (nab)-paclitaxel patients previously treated advanced pancreatic adenocarcinoma assess objective response rate.Patients (n = 20) received fixed-dose...
Abstract Metastatic castration-resistant prostate cancer (mCRPC) remains a significant clinical challenge, with patients often developing resistance to androgen receptor (AR)-axis-targeted therapies such as Abiraterone and Enzalutamide. A key mechanism involves the AR splice variant AR-V7, which drives tumor progression poor prognosis. To address need for novel, effective treatment strategies, we conducted unbiased high-throughput screening (HTS) discover highly synergistic drug combinations...
Abstract There is an unmet need to develop novel treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). Patients often resistance hormonal therapies that target the AR-axis (e.g., abiraterone, enzalutamide). A splice variant of AR, AR-V7, associated these inhibitors as well mCRPC progression and poor prognoses. We embarked upon a high-throughput screen identify synergistic combinations targeted using two CRPC cell lines, LNCaP95 VCaP-CR. The goal drug...
While immunotherapy has demonstrated remarkable success in other malignancies, its efficacy prostate cancer remains limited. Organoid models, capable of recapitulating patient-specific therapeutic responses, offer a promising platform for studying tumor biology and treatment responses. However, their utility modeling immune interactions underdeveloped. To address this, we established an vitro co-culture system organoids cells to investigate tumor-immune identify novel targets aggressive...
Breast cancer metastasis is a leading cause of cancer-related death women in the United States. A hurdle advancing metastasis-targeted intervention phenotypic heterogeneity between primary and secondary lesions. To identify metastasis-specific gene expression profiles we performed RNA-sequencing breast mouse models; analyzing metastases from models various drivers routes. We contrasted identified common, targetable signatures. Allograft exhibited more mesenchymal-like than genetically...
Abstract The blood–tumor barrier (BTB) limits the entry of effective chemotherapeutic agents into brain for treatment malignant tumors like glioblastoma. Poor drug across BTB allows infiltrative glioma stem cells to evade therapy and develop resistance. Regadenoson, an FDA-approved adenosine A2A receptor (A2AR) agonist, has been shown increase delivery blood–brain in non–tumor-bearing rodents without a defined mechanism enhancing permeability. Here, we characterize time-dependent impact...
We demonstrated that a large primary and small untreated distant breast cancer could be controlled by local treatment with our light-activatable paclitaxel (PTX) prodrug. hypothesized the treated tumor would damaged combinational effects of photodynamic therapy (PDT) locally released PTX suppressed systemic antitumor effects. Syngeneic rat models (single- two-tumor models) were established on Fischer 344 rats subcutaneous injection MAT B III cells. The injected prodrug (dose: 1 umole kg
Abstract Purpose: LMB-100 recombinant immunotoxin (iTox) consists of a mesothelin-binding Fab for targeting and modified Pseudomonas exotoxin A payload. Preclinical studies showed that combining taxanes with iTox results in synergistic antitumor activity. The primary objectives this phase I/II study were to determine the maximum tolerated dose (MTD) when given nanoalbumin bound (nab)-paclitaxel participants previously treated advanced pancreatic adenocarcinoma assess objective response rate....
<p>Adverse events attributed to nab-paclitaxel</p>
<p>Supplemental Figure 4</p>
<p>Supplemental Figure Legends</p>
<p>Serious adverse events unrelated to research.</p>
<p>Order of study arm enrollment is displayed graphically</p>
<p>Serious adverse events unrelated to research.</p>
<p>Supplemental Figure Legends</p>
<p>Supplemental Figure 4</p>
<p>Order of study arm enrollment is displayed graphically</p>
<p>Adverse events attributed to nab-paclitaxel</p>
<div>AbstractPurpose:<p>LMB-100 is a recombinant immunotoxin (iTox) consisting of mesothelin-binding Fab for targeting and modified <i>Pseudomonas</i> exotoxin A payload. Preclinical studies showed that combining taxanes with iTox results in synergistic antitumor activity. The objectives this phase I/II study were to determine the MTD LMB-100 when administered nanoalbumin bound (nab)-paclitaxel patients previously treated advanced pancreatic adenocarcinoma assess...
<div>AbstractPurpose:<p>LMB-100 is a recombinant immunotoxin (iTox) consisting of mesothelin-binding Fab for targeting and modified <i>Pseudomonas</i> exotoxin A payload. Preclinical studies showed that combining taxanes with iTox results in synergistic antitumor activity. The objectives this phase I/II study were to determine the MTD LMB-100 when administered nanoalbumin bound (nab)-paclitaxel patients previously treated advanced pancreatic adenocarcinoma assess...
<p>Workflow and aRT-PCR results</p>